Recent Financings of Private Companies (09/11)
This article was originally published in Start Up
Executive Summary
Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.
You may also be interested in...
Taisho To Go Private To Aid 'Dynamic' Restructuring, R&D Investment
The largest shareholder in major Japanese pharma firm Taisho, the founding Uehara family, intends to smooth the way to the restructuring and expansion of the business by acquiring and delisting all of its stock. The nearly $5bn size of the deal would makes it the biggest management buyout in Japanese corporate history.
Patent ‘March-In’ Policy Shift Will Likely Drive Uncertainty More Than Price Drops
Biden administration’s new framework will consider whether a product’s price is reasonable in deciding whether to exercise march-in rights. Numerous other factors could limit provision’s impact, but industry is concerned it will discourage firms from licensing government-funded inventions.
Lack Of Competition Equals Higher Drug Prices: HHS Analysis Is Slogan In Search Of Solutions
Findings could provide a basis for future policy interventions, the department says. Speeding generics and biosimilars would seem a natural outshoot of the conclusions, but the report does not contain any recommendations.